Viatris (Viatris) Days Sales Outstanding

: 71.99 (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

Viatris's average Accounts Receivable for the three months ended in Dec. 2023 was $3,027 Mil. Viatris's Revenue for the three months ended in Dec. 2023 was $3,837 Mil. Hence, Viatris's Days Sales Outstanding for the three months ended in Dec. 2023 was 71.99.

The historical rank and industry rank for Viatris's Days Sales Outstanding or its related term are showing as below:

VTRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.78 Med: 89.5 Max: 99.78
Current: 73.08

During the past 13 years, Viatris's highest Days Sales Outstanding was 99.78. The lowest was 71.78. And the median was 89.50.

VTRS's Days Sales Outstanding is ranked worse than
50.85% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 72.07 vs VTRS: 73.08

Viatris's Days Sales Outstanding increased from Dec. 2022 (71.49) to Dec. 2023 (71.99).

Viatris Days Sales Outstanding Historical Data

The historical data trend for Viatris's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

80.24

99.78

78.22

78.76

71.78

Viatris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																71.49	76.66	71.55	73.55	71.99

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris Days Sales Outstanding Distribution

For the Drug Manufacturers industry and Healthcare sector, Viatris's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Viatris's Days Sales Outstanding falls into.

Viatris Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Viatris's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (3243.8	+	2823.8)	/	2 )	/	15426.9	*	365
=	3033.8					/	15426.9	*	365
=	71.78

Viatris's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (3231	+	2823.8)	/	2 )	/	3837.3	*	365 / 4
=	3027.4					/	3837.3	*	365 / 4
=	71.99

Viatris (NAS:VTRS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Viatris Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Viatris's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (Viatris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Executives

Andrew Cuneo	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Xiangyang (sean) Ni	officer: President, Greater China	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury	director, officer: Executive Chairman	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell	director
Brian Roman	officer: Global General Counsel	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro	officer: See Remarks	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
James M Kilts	director	120 PARK AVE, NEW YORK NY 10017
Melina E Higgins	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Ian C Read	director	PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Dillon Joellen Lyons	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL